Subscribe to RSS
Cytotoxic Lesion in the Splenium of Corpus Callosum Secondary to Subacute Methotrexate Neurotoxicity
Methotrexate neurotoxicity can present with a wide spectrum of neurologic symptoms and brain magnetic resonance imaging (MRI) typically demonstrates cerebral edema, demyelination, multifocal white matter necrosis, and atrophy relatively selective for the deep cerebral white matter. Here, we report a case of subacute methotrexate neurotoxicity in a 40-year-old man with B cell acute lymphoblastic leukemia. Brain MRI showed cytotoxic lesion in the splenium of corpus callosum and left middle cerebellar peduncle. Patient significantly improved 24 hours after receiving oral dextromethorphan. Methotrexate neurotoxicity should be suspected in any symptomatic patient receiving high dose of methotrexate or intrathecal methotrexate therapy. Dextromethorphan should be considered in these patients as it can modulate the excitatory responses to homocysteine and its metabolite which are usually elevated in such patients.
04 August 2021 (online)
© 2021. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Limited
A-12, Second Floor, Sector -2, Noida-201301, Uttar Pradesh
- 1 FDA methotrexate label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf. Accessed June 9, 2021
- 2 Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 2004; 25 (10) 1688-1695
- 3 Ebner F, Ranner G, Slavc I. et al. MR findings in methotrexate-induced CNS abnormalities. AJNR Am J Neuroradiol 1989; 10 (05) 959-964
- 4 Smith B. Brain damage after intrathecal methotrexate. J Neurol Neurosurg Psychiatry 1975; 38 (08) 810-815
- 5 Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatr Neurol 2014; 50 (06) 625-629
- 6 Boogerd W, vd Sande JJ, Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 1988; 51 (10) 1277-1283
- 7 Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4 (04) 266-273
- 8 Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49 (1-2) 92-104
- 9 Kishi S, Griener J, Cheng C. et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21 (16) 3084-3091
- 10 Drachtman RA, Cole PD, Golden CB. et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002; 19 (05) 319-327
- 11 Fustino NJ, Juhl K, Leister J. Dextromethorphan administration on day 0 and day 7 for secondary prevention of methotrexate-induced neurotoxicity in childhood acute lymphoblastic leukemia: a retrospective case series. J Pediatr Hematol Oncol 2020; doi: DOI: 10.1097/MPH.0000000000001714.
- 12 von R Kummer, Dzialowski I. Imaging of cerebral ischemic edema and neuronal death. Neuroradiology 2017; 59 (06) 545-553
- 13 Starkey J, Kobayashi N, Numaguchi Y, Moritani T. Cytotoxic lesions of the corpus callosum that show restricted diffusion: mechanisms, causes, and manifestations. Radiographics 2017; 37 (02) 562-576
- 14 Goursaud S, Kozlova EN, Maloteaux JM, Hermans E. Cultured astrocytes derived from corpus callosum or cortical grey matter show distinct glutamate handling properties. J Neurochem 2009; 108 (06) 1442-1452